178 related articles for article (PubMed ID: 37829759)
1. Potential efficacy of dopaminergic antidepressants in treatment resistant anergic-anhedonic depression results of the chronic anergic-anhedonic depression open trial - CADOT.
Dormegny-Jeanjean LC; de Billy C; Mainberger O; Weibel S; Schorr B; Obrecht A; Landré L; Berna F; Causin JB; Blanc F; Danila V; Tomsa M; Pfleger G; Meyer C; Humbert I; Javelot H; Meyer G; Bertschy G; Foucher JR
Front Psychiatry; 2023; 14():1194090. PubMed ID: 37829759
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
Tundo A; de Filippis R; Proietti L
World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression.
Dormegny-Jeanjean LC; Mainberger OAE; de Crespin de Billy C; Obrecht A; Danila V; Erb A; Arcay HM; Weibel S; Blanc F; Meyer G; Tomsa M; Bertschy G; Duval F; Foucher JR
Encephale; 2024 Apr; 50(2):137-142. PubMed ID: 37005193
[TBL] [Abstract][Full Text] [Related]
5. Psychological therapies for treatment-resistant depression in adults.
Ijaz S; Davies P; Williams CJ; Kessler D; Lewis G; Wiles N
Cochrane Database Syst Rev; 2018 May; 5(5):CD010558. PubMed ID: 29761488
[TBL] [Abstract][Full Text] [Related]
6. PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression.
Au-Yeung SK; Griffiths J; Roberts S; Edwards C; Yu LM; Bogacz R; Rendell J; Attenburrow MJ; Watson S; Chan F; Cipriani A; Cleare A; Harmer CJ; Kessler D; Evans J; Lewis G; Singh I; Simon J; Harrison PJ; Cowen P; Shanyinde M; Geddes J; Browning M
Evid Based Ment Health; 2022 May; 25(2):77-83. PubMed ID: 34810175
[TBL] [Abstract][Full Text] [Related]
7. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
8. Childhood maltreatment and clinical severity of treatment-resistant depression in a French cohort of outpatients (FACE-DR): One-year follow-up.
Yrondi A; Aouizerate B; Bennabi D; Richieri R; D'Amato T; Bellivier F; Bougerol T; Horn M; Camus V; Courtet P; Doumy O; Genty JB; Holtzmann J; Lancon C; Leboyer M; Llorca PM; Maruani J; Moirand R; Molière F; Samalin L; Schmitt L; Stephan F; Turecki G; Vaiva G; Walter M; Petrucci J; ; Haffen E; El-Hage W
Depress Anxiety; 2020 Apr; 37(4):365-374. PubMed ID: 31999402
[TBL] [Abstract][Full Text] [Related]
9. Mindfulness-based cognitive therapy (MBCT) versus the health-enhancement program (HEP) for adults with treatment-resistant depression: a randomized control trial study protocol.
Eisendrath SJ; Gillung EP; Delucchi KL; Chartier M; Mathalon DH; Sullivan JC; Segal ZV; Feldman MD
BMC Complement Altern Med; 2014 Mar; 14():95. PubMed ID: 24612825
[TBL] [Abstract][Full Text] [Related]
10. The effect of the time to remission on residual symptoms and functioning among depressive patients.
Zhu XQ; Mayes TL; Qi N; Feng L; Feng Y; Wu WY; Hu YD; Xiao L; Wang G
J Affect Disord; 2023 Jan; 320():667-673. PubMed ID: 36209781
[TBL] [Abstract][Full Text] [Related]
11. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.
Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH
Am J Psychiatry; 2019 May; 176(5):358-366. PubMed ID: 30922100
[TBL] [Abstract][Full Text] [Related]
12. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
Thobois S; Lhommée E; Klinger H; Ardouin C; Schmitt E; Bichon A; Kistner A; Castrioto A; Xie J; Fraix V; Pelissier P; Chabardes S; Mertens P; Quesada JL; Bosson JL; Pollak P; Broussolle E; Krack P
Brain; 2013 May; 136(Pt 5):1568-77. PubMed ID: 23543483
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of atypical antipsychotics in depressive syndromes].
Quintin P; Thomas P
Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
[TBL] [Abstract][Full Text] [Related]
14. Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression.
Kim T; Xu C; Amsterdam JD
J Affect Disord; 2019 May; 250():199-203. PubMed ID: 30861462
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials.
Jha MK; South C; Trivedi J; Minhajuddin A; Rush AJ; Trivedi MH
Int J Neuropsychopharmacol; 2019 May; 22(5):339-348. PubMed ID: 30958879
[TBL] [Abstract][Full Text] [Related]
16. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
[TBL] [Abstract][Full Text] [Related]
17. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
18. Prediction of longer-term outcome of treatment-resistant depression in tertiary care.
Fekadu A; Rane LJ; Wooderson SC; Markopoulou K; Poon L; Cleare AJ
Br J Psychiatry; 2012 Nov; 201(5):369-75. PubMed ID: 22955008
[TBL] [Abstract][Full Text] [Related]
19. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Cha DS; Lee Y; Gill H; Majeed A; Phan L; Nasri F; Ho R; Lin K; Subramaniapillai M; Kratiuk K; Mansur RB; Rosenblat JD
J Affect Disord; 2020 Nov; 276():570-575. PubMed ID: 32871688
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
